Protalix BioTherapeutics, Inc.(PLX)— Stock Profile, AI Score & Financials
Healthcare · NYSE · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
Protalix BioTherapeutics, Inc. (PLX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores PLX at 58.0/100 on a 32-signal composite quality model, placing it at rank #1,056 of 2,961 stocks — the top half of the AI-ranked universe. PLX scores in the top quartile across balance sheet strength (96.1), profitability (87.3). Areas of concern include institutional flow (11.8) and revenue scale (12.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 26.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Protalix BioTherapeutics, Inc. reports quarterly revenue of $19.9M, net income of $3.8M, an operating margin of 23.5%. Top institutional holders of PLX by reported 13-F value include BlackRock, RENAISSANCE TECHNOLOGIES, STATE STREET, based on the most recent SEC filings. PLX trades on the NYSE exchange and files with the SEC under CIK 1006281. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PLX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Protalix BioTherapeutics, Inc. directly from SEC EDGAR.
AI Quality Score
58.0/100
AI Rank
#1,056
Revenue
$19.9M
Net Income
$3.8M
Free Cash Flow
$-11.0M
Operating Margin
23.5%
PLX key financials by period
Protalix BioTherapeutics, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2025
10-K
$52.7M
$-6.6M
-10.4%
FY 2024
10-K
$53.4M
$2.9M
7.3%
FY 2023
10-K
$65.5M
$8.3M
16.0%
FY 2022
10-K
$47.6M
$-14.9M
-27.3%
FY 2021
10-K
$38.4M
$-27.6M
-53.4%
FY 2020
10-K
$62.9M
$-6.5M
4.3%
Institutions holding PLX
Institutional investors reporting a position in Protalix BioTherapeutics, Inc. on SEC Form 13F.
AI-extracted from the 10-Q filed 2026-08-12 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Protalix's Q2 FY2026 revenue was $19.9M, up from $15.7M a year earlier, as a 28% increase in product sales — led by Chiesi — helped lift net income to $3.8M from $0.2M.
Biggest Revenue Drivers
Revenues from selling goods$19.8M+28% YoY
Increase resulted primarily from an increase in sales to Chiesi
Revenues from license and R&D services$68K-$150K YoY
Decrease resulted from a decrease in the amount of services provided to Chiesi
Biggest Revenue Drivers
Total revenue: $19.9M
Revenues from selling goods$19.8M+28% YoY
Increase resulted primarily from an increase in sales to Chiesi
Within Revenues from selling goods
Chiesi (Fabry disease)$14.0M+$4,242K YoY
Increase in sales to Chiesi
Pfizer (Gaucher disease)$4.3M-$1,368K YoY
Decrease resulted primarily from Pfizer's purchases to address unexpected manufacturing issues at Pfizer in 2025
Fiocruz (Brazil)$1.5M+$1,514K YoY
Increase resulted primarily from the timing of deliveries
Revenues from license and R&D services$68K-$150K YoY
Decrease resulted from a decrease in the amount of services provided to Chiesi
Largest Expense Items
Cost of revenues$7.8M+32% YoY
Increase resulted primarily from an increase in sales to Chiesi and to Fiocruz, partially offset by a decrease in sales to Pfizer
Research and development expenses, net$4.4M-27% YoY
Decrease resulted primarily from a $2.1 million grant recorded under the new Israeli R&D law as a reduction of R&D expenses
Selling, general, and administrative expenses$3.1M+19% YoY
Increase resulted primarily from higher salary and related expenses and selling expenses
Margins: Operating income rose to $4.7M from $1.2M a year earlier as 28% growth in product sales and a $2.1M Israeli R&D grant offset a 32% increase in cost of revenues tied to higher Chiesi and Fiocruz shipments.
Watch Items from the Filing
Chiesi, Pfizer, and Fiocruz are Protalix's only three commercial customers, contributing $14.0M, $4.3M, and $1.5M respectively of the $19.8M in product sales this quarter.
Fiocruz has not satisfied certain purchase commitments under the Brazil Agreement, which could have a material adverse effect and may lead to termination of the agreement.
New Section 232 tariffs on pharmaceutical products and APIs, announced April 2, 2026 and generally effective September 2026, could adversely affect the company's ability to commercialize products in the U.S.
Pfizer's Q2 2025 purchases to address unexpected manufacturing issues inflated the prior-year comparison, contributing to a $1,368K YoY decline in Pfizer sales; order timing does not reflect patient demand.
Net income was $3.8M in Q2 2026 versus $0.2M in Q2 2025, aided by a $2.1M Israeli R&D grant recognized as a reduction to R&D expense.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
